乙醛脱氢酶1和转化生长因子-β2在三阴性乳腺癌中的表达及临床意义

doi:10.3760/cma.j.issn.1673-422X.2017.11.001

国际肿瘤学杂志 ›› 2017, Vol. 44 ›› Issue (11): 801-805.doi: 10.3760/cma.j.issn.1673-422X.2017.11.001

• 论著 • 下一篇

乙醛脱氢酶1和转化生长因子-β2在三阴性乳腺癌中的表达及临床意义

郭崇勇,李永梅,李柏成,周凌,张建,贾宗师

256600 山东省滨州市人民医院乳腺外科（普外三科）（郭崇勇、贾宗师），妇科（李永梅），病理科（李柏成、张建）；上海市第一人民医院分院普外科（周凌）

收稿日期:2017-08-16 出版日期:2017-11-08 发布日期:2017-11-24
通讯作者: 郭崇勇 E-mail:guochongyong66@163.com
基金资助:
山东省自然科学基金（ZR2014HP036）

Expressions and clinical significances of aldehyde dehydrogenase 1 and transforming growth factor-β2 in triple negative breast cancer

Guo Chongyong, Li Yongmei, Li Bocheng, Zhou Ling, Zhang Jian, Jia Zongshi

Department of Breast Surgery （Third Department of General Surgery）, Binzhou People′s Hospital of Shandong Province, Binzhou 256600, China

Received:2017-08-16 Online:2017-11-08 Published:2017-11-24
Contact: Guo Chongyong E-mail:guochongyong66@163.com
Supported by:
Natural Science Foundation of Shandong Province of China (ZR2014HP036)

摘要/Abstract

摘要： 目的探讨乳腺肿瘤干细胞标志物乙醛脱氢酶1（ALDH1）和转化生长因子-β2（TGF-β2）在三阴性乳腺癌中的表达及其临床意义。方法采用免疫组织化学染色法检测60例三阴性乳腺癌患者肿瘤组织中ALDH1和TGF-β2蛋白的表达，并进行相关性分析和无瘤生存期、总生存期分析。结果在60例乳腺癌原发灶中，ALDH1蛋白和TGFβ2蛋白阳性表达分别为23例（38.33%）和38例（63.33%）。ALDH1蛋白在乳腺癌组织中的阳性表达与肿瘤大小（χ2=0.307，P=0.580）、组织学分级（χ2=4.244，P=0.120）、临床分期（χ2=0.982，P=0.612）以及淋巴结转移（χ2=1.111，P=0.292）均无关。TGFβ2蛋白在乳腺癌组织中的阳性表达与组织学分级（χ2=4.651，P=0.098）、淋巴结转移（χ2=3.513，P=0.061）、临床分期（χ2=1.310，P=0.519）和肿瘤大小（χ2=0.629，P=0.428）无关。ALDH1阳性患者的无瘤生存期［（38.43±3.86）个月∶（53.38±2.58）个月］、总生存期［（42.00±3.11）个月∶（53.84±2.19）个月］显著短于ALDH1阴性患者，差异均有统计学意义（χ2=8.490，P=0.004；χ2=11.270，P=0.001）。TGF-β2阳性患者的无瘤生存期［（42.81±3.32）个月∶（54.72±2.50）个月］、总生存期［（44.74±2.68）个月∶（57.18±1.55）个月］显著短于TGF-β2阴性患者，差异均有统计学意义（χ2=4.300，P=0.038；χ2=8.900，P=0.003）。ALDH1与TGF-β2蛋白在乳腺癌组织中的阳性表达呈正相关（r=0.360，P=0.005）。结论 ALDH1可作为判断预后的独立指标，TGF-β2信号通路的激活可能参与调控三阴性乳腺癌中肿瘤干细胞亚群。

关键词: 乳腺肿瘤, 肿瘤干细胞, 转化生长因子β2, 乙酰脱氢酶1

Abstract: Objective To investigate the expressions and clinical significances of breast cancer stem cell markers such as aldehyde dehydrogenase 1 (ALDH1) and transforming growth factorβ2 (TGFβ2) in patients with triple negative breast cancer. MethodsSamples of 60 triple negative breast cancer tissues were investigated for the expressions of ALDH1 and TGFβ2 proteins by immunohistochemical staining. The correlation analysis, diseasefree survival analysis and overall survival analysis were performed. ResultsThe positive expressions of ALDH1 protein and TGFβ2 protein in the 60 breast cancer primary lesions were 23 cases (38.33%) and 38 cases (63.33%) respectively. The expression of ALDH1 protein was not correlated with tumor size (χ2=0.307, P=0.580), histological grade (χ2=4.244, P=0.120), clinical stage (χ2=0.982, P=0.612) or lymph node metastasis (χ2=1.111, P=0.292). The expression of TGFβ2 protein was not correlated with histological grade (χ2=4.651, P=0.098), lymph node metastasis (χ2=3.513, P=0.061), clinical stage (χ2=1.310, P=0.519) or tumor size (χ2=0.629, P=0.428). The diseasefree survival time ［(38.43±3.86) months vs. (53.38±2.58) months］ and the overall survival time ［(42.00±3.11) months vs. (53.84±2.19) months］ of ALDH1positive patients were significantly shorter than those of ALDH1negative patients, and the differences were statistically significant (χ2=8.490, P=0.004; χ2=11.270, P=0.001). The diseasefree survival time ［(42.81±3.32) months vs. (54.72±2.50) months］ and the overall survival time ［(44.74±2.68) months vs. (57.18±1.55) months］ of TGFβ2 positive patients were significantly shorter than those of TGFβ2negative patients, and the differences were statistically significant (χ2=4.300, P=0.038; χ2=8.900, P=0.003). The expression of ALDH1 protein was positively correlated with the expression of TGFβ2 protein (r=0.360, P=0.005). ConclusionThe ALDH1 phenotype is an independent predictor of poor prognosis. The activation of TGFβ2 signaling pathway may be involved in the regulation of triplenegative breast cancer stem cells.

Key words: Breast neoplasms, Neoplastic stem cells, Transforming growth factor beta 2, Aldehyde dehydrogenase 1

郭崇勇,李永梅,李柏成,周凌,张建,贾宗师. 乙醛脱氢酶1和转化生长因子-β2在三阴性乳腺癌中的表达及临床意义[J]. 国际肿瘤学杂志, 2017, 44(11): 801-805.

Guo Chongyong, Li Yongmei, Li Bocheng, Zhou Ling, Zhang Jian, Jia Zongshi. Expressions and clinical significances of aldehyde dehydrogenase 1 and transforming growth factor-β2 in triple negative breast cancer[J]. Journal of International Oncology, 2017, 44(11): 801-805.

参考文献

［1］ Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell［J］. Nat Med, 1997, 3(7): 730-737. ［2］ CharafeJauffret E, Ginestier C, Iovino F, et al. Aldehyde dehydrogenase 1positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer［J］. Clin Cancer Res, 2010, 16(1): 45-55. DOI: 10.1158/1078-0432.CCR-09-1630. ［3］ Ginestier C, Hur MH, CharafeJauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome［J］. Cell Stem Cell, 2007, 1(5): 555-567. DOI: 10.1016/j.stem.2007.08.014. ［4］ Mani SA, Guo W, Liao MJ, et al. The epithelialmesenchymal transition generates cells with properties of stem cells［J］. Cell, 2008, 133(4): 704-715. DOI: 10.1016/j.cell.2008.03.027. ［5］ Zubeldia IG, Bleau AM, Redrado M, et al. Epithelial to mesenchymal transition and cancer stem cell phenotypes leading to liver metastasis are abrogated by the novel TGFβ1targeting peptides P17 and P144［J］. Exp Cell Res, 2013, 319(3): 1222. DOI: 10.1016/j.yexcr.2012.11.004. ［6］ Kim S, Han J, Jeon M, et al. Silibinin inhibits triple negative breast cancer cell motility by suppressing TGF-β2 expression［J］. Tumour Biol, 2016, 37(8): 11397-11407. DOI: 10.1007/s13277-016-5000-7. ［7］ Zhou L, Li K, Luo Y, et al. Novel prognostic markers for patients with triplenegative breast cancer［J］. Hum Pathol, 2013, 44(10): 2180-2187. DOI: 10.1016/j.humpath.2013.03.021. ［8］ Yu P, Zhou L, Wang JF, et al. Prognostic relevance of ALDH1 in breast cancer: a clinicopathological study of 96 cases［J］. ChineseGerman J Clin Oncol, 2010, 9(1): 31-35. DOI: 10.1007/s10330-009-0178-4. ［9］周凌, 虞佩, 王建丰, 等. 乙酰脱氢酶1蛋白在乳腺癌中的表达及临床意义［J］. 肿瘤, 2009, 29(7): 663-667. DOI: 10.3781/j.issn.1000-7431.2009.07.013. ［10］ Ma F, Li H, Li Y, et al. Aldehyde dehydrogenase 1 (ALDH1) expression is an independent prognostic factor in triple negative breast cancer (TNBC)［J］. Medicine (Baltimore), 2017, 96(14): e6561. DOI: 10.1097/MD.0000000000006561. ［11］ Heldin CH, Landstrm M, Moustakas A. Mechanism of TGFbeta signaling to growth arrest, apoptosis, and epithelialmesenchymal transition［J］. Curr Opin Cell Biol, 2009, 21(2): 166-176. DOI: 10.1016/j.ceb.2009.01.021. ［12］ Ikushima H, Miyazono K. TGFbeta signalling: a complex web in cancer progression［J］. Nat Rev Cancer, 2010, 10(6): 415-424. DOI: 10.1038/nrc2853. ［13］ Yang L, Pang Y, Moses HL. TGFbeta and immune cells: an important regulatory axis in the tumor microenvironment and progression［J］. Trends Immunol, 2010, 31(6): 220-227. DOI: 10.1016/j.it.2010.04.002. ［14］ Yang HP, Schneider SS, Chisholm CM, et al. Association of TGFβ2 levels in breast milk with severity of breast biopsy diagnosis［J］. Cancer Causes Control, 2015, 26(3): 345-354. DOI: 10.1007/s1055201404988. ［15］ MuraokaCook RS, Dumont N, Arteaga CL. Dual role of transforming growth factor beta in mammary tumorigenesis and metastatic progression［J］. Clin Cancer Res, 2005, 11(2 Pt 2): 937s943s. ［16］ Bierie B, Moses HL. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer［J］. Nat Rev Cancer, 2006, 6(7): 506-520. DOI: 10.1038/nrc1926. ［17］ Bueno L, de Alwis DP, Pitou C, et al. Semimechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type Ⅰ receptor TGFbeta kinase antagonist, in mice［J］. Eur J Cancer, 2008, 44(1): 142-150. DOI: 10.1016/j.ejca.2007.10.008. ［18］ Kim S, Lee J, Jeon M, et al. Elevated TGF-β1 and β2 expression accelerates the epithelial to mesenchymal transition in triplenegative breast cancer cells［J］. Cytokine, 2015, 75(1): 151-158. DOI: 10.1016/j.cyto.2015.05.020. ［19］ Bhola NE, Balko JM, Dugger TC, et al. TGF-β inhibition enhances chemotherapy action against triplenegative breast cancer［J］. J Clin Invest, 2013, 123(3): 1348-1358. DOI: 10.1172/JCI65416. ［20］郭崇勇, 李克, 周凌, 等. 长程多柔比星化疗富集乳腺肿瘤干细胞［J］. 肿瘤, 2012, 32(1): 27-31. DOI: 10.3781/j.issn.1000-7431.2012.01.005. ［21］ Hoshino Y, Nishida J, Katsuno Y, et al. Smad4 decreases the population of pancreatic cancerinitiating cells through transcriptional repression of ALDH1A1［J］. Am J Pathol, 2015, 185(5): 1457-1470. DOI: 10.1016/j.ajpath.2015.01.011.

[1]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[3]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[4]	陈波光, 王苏贵, 张永杰. 血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[5]	顾花艳, 朱腾, 郭贵龙. 乳房微生物群与乳腺癌：现状与未来[J]. 国际肿瘤学杂志, 2024, 51(1): 55-58.
[6]	王景, 许文婷. 中性粒细胞与淋巴细胞比值、癌胚抗原联合凝血指标对直径≤1.0 cm的良恶性乳腺结节鉴别诊断价值研究[J]. 国际肿瘤学杂志, 2023, 50(9): 520-526.
[7]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英. HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[8]	冯东旭, 吴炜, 高平发, 王军, 施丽娟, 陈大伟, 李文兵, 张美峰. miR-451通过调控Rho/ROCK1信号通路对乳腺癌细胞糖酵解及凋亡的影响[J]. 国际肿瘤学杂志, 2023, 50(8): 449-456.
[9]	王文德, 曾德. 乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356.
[10]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[11]	朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏. HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240.
[12]	周婷, 徐少华, 梅林. 贝伐珠单抗联合卡培他滨治疗晚期乳腺癌的有效性及安全性[J]. 国际肿瘤学杂志, 2023, 50(3): 144-149.
[13]	黎立喜, 张娣, 罗扬, 马飞. PARP抑制剂在乳腺癌中的临床应用[J]. 国际肿瘤学杂志, 2023, 50(2): 91-96.
[14]	陈群响, 张晓钰, 张妍, 张凯翔, 李捷, 陈曦. 伊尼妥单抗联合长春瑞滨治疗HER2阳性转移性乳腺癌1例[J]. 国际肿瘤学杂志, 2023, 50(12): 763-765.
[15]	耿睿, 马俊强, 郭强, 牛钊峰. 老年乳腺癌患者的综合治疗方式选择倾向及其影响因素[J]. 国际肿瘤学杂志, 2023, 50(11): 650-654.

乙醛脱氢酶1和转化生长因子-β2在三阴性乳腺癌中的表达及临床意义

Expressions and clinical significances of aldehyde dehydrogenase 1 and transforming growth factor-β2 in triple negative breast cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价